BioAge Labs Plunges Over 60% After Novo’s ZEUS Trial Failure — Citi Says the Sell-Off Is Overdone
BioAge Labs shares fell over 60% after Novo Nordisk’s ZEUS trial failed to cut MACE. Citi says the sell-off is excessive despite negative ASCVD impact.
/ 5 items
#BIOA↓
Needham Initiates Buy Rating on BioAge Labs with $50 Price Target
Analysts are bullish on lead asset BGE-102, an oral NLRP3 inhibitor for cardiovascular risk in obese patients.
Hot Biotech Upgrades: Zenas BioPharma and BioAge Labs Shine Bright
Wall Street analysts are bullish on Zenas BioPharma and BioAge Labs with strong upgrades, highlighting near-term FDA potential and promising drug data for big growth in 2026.
Piper Sandler Starts Coverage on BioAge Labs With Buy Rating and $73 Target
Piper Sandler initiates coverage of BioAge Labs with an Overweight rating, highlighting strong early data for its lead drug BGE-102 and key upcoming catalysts.
Citi Upgrades BioAge Labs Stock on Promising Obesity Drug Potential
Citi analyst upgrades BioAge Labs to Buy with $10 price target, citing BGE-102 obesity drug as potentially game-changing treatment option.